Nilotinib resistance in leukaemia is often caused by the mutation of threonine 315 in BCR‐ABL into a bulkier isoleucine that reduces the drug affinity for this kinase (Weisberg et al, 2007). The gene discussed is ABL1; the disease is leukemia.